Oct 1, 2026 - 6 AI models call the biggest movers in the morning session. 3 models finished positive

Asked Oct 1, 10:16 AM EDT (morning session). GPT-5.6 Sol, Muse Spark 1.1, Perplexity, Claude Sonnet 5.5, Gemini 1.5 Pro and DeepSeek answered the same standard prompt independently. Window: from Oct 1, 10:16 AM EDT to Oct 2, 10:16 AM EDT, the same time one session later. Benchmark: SPY.

Five direction-adjusted close-to-close returns; a down call reverses the sign. The score is the mean signed return, without subtracting the benchmark. In each chart SPY is on the left and the picks on the right, every candle drawn from zero to that asset's move; ✓ marks a pick that moved the way it was called.

Model	Correct	Hit rate	Return	SPY	Directional return
GPT-5.6 Sol	2/5	40.00%	-0.68%	1.38%	-0.68%
Muse Spark 1.1	1/5	20.00%	-1.90%	1.38%	-1.90%
Perplexity	1/5	20.00%	-1.59%	1.38%	-1.59%
Claude Sonnet 5.5	3/5	60.00%	1.42%	1.38%	1.42%
Gemini 1.5 Pro	5/5	100.00%	2.92%	1.38%	2.92%
DeepSeek	2/5	40.00%	0.21%	1.38%	0.21%

GPT-5.6 Sol

View full picks and reasoning

The September 30 mover set was unusually event-driven. Patent litigation produced the largest biotechnology dislocations, while analyst actions and earnings reactions drove several liquid technology names. For the October 1 to October 2 window, the strongest continuation case is United Therapeutics because its legal victory directly improves competitive positioning, while Jabil has the clearest reversal setup because its 10% source-session decline occurred despite earnings and forward guidance above expectations. Liquidia remains exposed to continuing legal repricing, although its already extreme two-day decline creates substantial squeeze and mean-reversion risk. FormFactor and Zeta Global have positive but less durable analyst-driven catalysts, making continuation forecasts lower confidence.

1. UTHR up — confidence 72%. Continuation up. United Therapeutics gained 12.55% on September 30 after a Delaware federal court ruled that Liquidia's YUTREPIA infringed two claims of United Therapeutics' '327 patent. This is a substantive catalyst rather than a speculative headline because the decision directly affects competitive economics in inhaled treprostinil and strengthens the position of Tyvaso. The main risk is profit-taking after a very large one-day revaluation and uncertainty over the final remedy and Liquidia's planned appeal. The latest traded price I could verify was $542.80 in September 30 after-hours trading; I could not obtain a refreshed October 1 regular-session UTHR quote before submission, so the stale date is retained rather than restating it as current. The reported 20-day dollar-volume figure is a conservative close-times-volume average calculated from the 20 source sessions through September 30 and floored rather than rounded upward.
   Return: -4.45%; alpha: -5.83%.
2. JBL up — confidence 68%. Reversal up. Jabil fell 10.03% on September 30 even though fiscal Q4 revenue and core EPS exceeded consensus and management issued fiscal 2027 revenue and EPS guidance above Wall Street expectations. The selloff was attributed largely to profit-taking and concerns that earnings growth would be back-end loaded, making the move fundamentally different from a deterioration-driven earnings collapse. That creates a credible one-session mean-reversion setup. The principal risks are continued multiple compression, high Treasury yields, and investors focusing on margin and free-cash-flow concerns despite the headline beat. A $290.81 October 1 fair-market-value quote was available as of 09:48 ET, making it the freshest verified quote used here. The 20-day dollar-volume figure is calculated from reported daily closes and volumes through September 30 and conservatively floored.
   Return: 4.87%; alpha: 3.49%.
3. LQDA down — confidence 66%. Continuation down. Liquidia collapsed 57.19% on September 30 after the U.S. District Court ruled that YUTREPIA infringed two valid United Therapeutics patent claims. This is a substantive legal and commercial catalyst because the remedy may affect an important marketed product, and the court directed the parties to submit a proposed judgment. Selling was still continuing on October 1: the freshest verified quote was $25.67 at 10:11 ET, down another 15.18% from the September 30 close. That ongoing price discovery supports continuation, although the forecast carries major reversal risk because a two-day collapse of this magnitude can produce violent short-covering and because Liquidia intends to appeal and contest the remedy. The 20-day dollar-volume figure is calculated from the 20 reported daily sessions through September 30 and conservatively floored.
   Return: 5.47%; alpha: -6.84%.
4. FORM up — confidence 61%. Continuation up. FormFactor rose 9.59% on September 30 after Deutsche Bank initiated coverage with a Buy rating and a $200 target, citing the company's position as a second-source supplier of GPU probe-card technology for Nvidia-related production at TSMC and additional high-bandwidth-memory testing opportunities. The catalyst is analyst-driven rather than a newly reported contract or earnings release, so it is less substantive than the patent and earnings events ranked above. Momentum is strong, but the stock had already advanced sharply before September 30, creating meaningful overbought and mean-reversion risk. The freshest price I could verify was $151.46 in October 1 extended trading at 08:20 ET; I could not verify a later regular-session FORM trade before submission. The 20-day dollar-volume figure is derived from reported daily close-times-volume observations through September 30 and conservatively floored.
   Return: 1.90%; alpha: 0.52%.
5. ZETA up — confidence 59%. Continuation up. Zeta Global rose 9.01% on September 30 after William Blair added the company to its Analyst Conviction List, while the broader fundamental backdrop includes continued investor enthusiasm around its Athena AI platform. The catalyst is credible but primarily analyst- and sentiment-driven rather than a fresh financial result, contract, or legal decision, so persistence is less certain. The freshest verified October 1 quote was $32.095 at 09:32:36 ET, above the September 30 close, which shows early follow-through but does not determine the forecast direction for the remaining window. Risks include rapid momentum exhaustion, valuation sensitivity, and reversal if the conviction-list effect proves temporary. The 20-day dollar-volume figure is calculated from reported daily closes and volumes through September 30 and conservatively floored.
   Return: -0.26%; alpha: -1.64%.

Full prediction and audit record

Muse Spark 1.1

View full picks and reasoning

October 1 2026 opened Q4 mixed. AI trade revived by Micron beat, Treasury yields rising. Top movers dominated by single-stock catalysts: 【entity-Accenture¦canonical_name=Accenture】 earnings, Vicor royalty guidance, Jabil guidance disappointment, and a binary patent ruling in PAH driving UTHR up and LQDA down sharply. Market breadth is narrow, favoring continuation of substantive catalysts but reversal risk on 20%+ gap ups.

1. ACN down — confidence 62%. Rank 1 gainer among large caps. Source session +23.94% on Q4 beat: EPS $3.29 vs $3.19 est, revenue $18.7B, record $84.5B annual bookings, FY27 growth guide 3-6%. Price used is live intraday quote $227.26, stale ~15min, previous close $183.37. Market cap ~$122.5B passes $1B, avg dollar volume ~$1.18B passes $20M, price >$5. Catalyst substantive, not speculative. Hypothesis reversal down: gap +23% on IT services is extreme and likely to fade as valuation catches up to modest growth guide.
   Return: -10.91%; alpha: 9.53%.
2. VICR up — confidence 68%. Top gainer +9.85% on Oct 1 after raising Q3 sequential growth guidance to >30% driven by increased royalties from first non-exclusive license for vertical power delivery. Price live $317.39, previous close $288.94, high $331. Source session close confirms $5, $1B, $20M filters. Market cap ~$13.01B in 2026, avg dollar volume ~$255M (853k shares * $300). Substantive catalyst. Continuation up expected as royalty model de-risks AI power delivery revenue.
   Return: -5.61%; alpha: -6.99%.
3. JBL down — confidence 65%. Top S&P 500 loser -10.03% despite beating Q4 by $0.35 EPS, opened $288.37, low $285.46. Market focused on timing of FY27 margin guidance $17.55 EPS and cautious outlook. Price $287.43 live, market cap $33.09B ($33089140000) passes, avg volume 1.2M shares ~$360M passes. Substantive earnings catalyst. Continuation down expected as guidance disappointment outweighs beat in high-expectations EMS name.
   Return: 4.87%; alpha: -6.25%.
4. LQDA down — confidence 70%. Largest decliner -57.19% after Delaware court ruled Liquidia infringed two UTHR patents on Tyvaso DPI, risking injunction. Trading halted then collapsed from $70.69 prior to $30.26 intraday low. Live price $26.1, market cap ~$6.3B ($6327383300) at source close, avg dollar volume $78.3M passes. Price >$5 before crash but still >$5 now. Catalyst highly substantive legal loss. Continuation down expected as market prices in loss of commercial path and potential damages.
   Return: 5.47%; alpha: -6.84%.
5. UTHR up — confidence 67%. Mirror winner to LQDA, +12.55% to $543.86 then $577.33 live, on same patent victory validating Tyvaso franchise. Previous close $541.89, change +$60.42, percent +12.55% per Zacks. Market cap ~$23.31B passes, avg dollar volume $76.3M passes, price $577 passes $5. Catalyst substantive IP protection extends monopoly. Continuation up expected as shorts cover LQDA and rotate to winner, with price near 52-week high $596.76.
   Return: -4.45%; alpha: -5.83%.

Full prediction and audit record

Perplexity

View full picks and reasoning

US equities opened mixed on October 1, 2026, with Treasury yields climbing to multi-year highs and investors digesting a softer inflation print alongside Fed policy uncertainty. The session featured extreme dispersion: Corteva plunged ~81% on a mechanical spinoff adjustment (Vylor seed business separation), while Liquidia collapsed ~57% on biotech sector weakness. FICO extended its prior-day 27% crash with another sharp decline on mortgage-scoring competition fears. On the upside, Accenture surged ~23% after strong Q4 earnings, and Synopsys jumped ~12% on AI chip-design partnerships. These moves reflect both substantive corporate events and speculative positioning around regulatory and competitive shifts.

1. FICO down — confidence 65%. Fair Isaac fell 26.5% on September 30 after FHFA announced a unified mortgage pricing grid placing VantageScore on equal footing with FICO Classic, while Rocket Mortgage adopted VantageScore 4.0 as its preferred model. The stock trades around $635 intraday on October 1, extending losses. Market cap ~$13B and 20-day average dollar volume exceeds $20M (avg volume ~450K shares at ~$600-900). Catalyst is substantive: structural competitive threat to FICO's mortgage scoring franchise, which underpins a large portion of profits. Direction: down. Hypothesis: continuation, as the regulatory change is permanent and analysts have cut price targets sharply (BofA to $700). Risk: oversold bounce if the market views the 27%+ drop as overdone. Source: https://www.ebc.com/forex/fico-stock-plunges-27-percent-mortgage-scoring-shakeup
   Return: 1.48%; alpha: -2.85%.
2. CTVA up — confidence 60%. Corteva dropped ~81% on October 1 due to the completion of its Vylor seed business spinoff, a mechanical adjustment rather than fundamental deterioration. Pre-spin close was $77.65 on September 30; post-spin indicative price is ~$15-20 for the crop-protection-only entity. Market cap was ~$52B pre-spin; post-spin entity likely ~$10-15B. Average daily volume ~4.6M shares at ~$78 equals ~$360M, well above the $20M threshold. The catalyst is non-substantive (accounting adjustment), but the extreme percentage move creates technical volatility. Direction: up. Hypothesis: reversal, as the drop is mechanical and the remaining crop-protection business is fundamentally sound. Risk: confusion over post-spin valuation and potential index rebalancing flows. Note: reference_price reflects pre-spin close as the latest verified regular-session quote; intraday October 1 quotes are unreliable due to the spinoff adjustment. Source: https://www.gurufocus.com/news/9105226/california-court-allows-cortevas-seed-business-spinoff-to-proceed-impacting-ctva-stock
   Return: -0.97%; alpha: -2.35%.
3. LQDA up — confidence 55%. Liquidia plunged 57.2% on September 30 to close at $30.26, marking it as the worst-performing healthcare stock in September with a 55% monthly decline. Market cap ~$2.7-3.3B. Average volume ~1.4-1.8M shares; at ~$50-70 pre-crash, 20-day avg dollar volume exceeded $20M. The catalyst appears speculative: broad biotech weakness and concerns about pulmonary hypertension competition, but no specific negative news identified. Direction: up. Hypothesis: reversal, as a 57% single-day drop without company-specific bad news suggests oversold conditions. Risk: continued sector rotation out of biotech or undisclosed fundamental issues. Source: https://www.gurufocus.com/news/9105328/liquidia-corp-lqda-leads-september-2026-healthcare-declines-with-553-drop
   Return: 5.47%; alpha: 4.09%.
4. ACN up — confidence 70%. Accenture surged 23.4% on October 1 after reporting Q4 revenue of $18.7B and annual revenue of $74.2B, beating expectations. Stock traded around $215-226 intraday. Market cap ~$130-140B. Average volume ~3-4M shares at ~$180-220 equals ~$600M+, well above $20M. Catalyst is substantive: strong earnings and AI-driven demand for consulting services. Direction: up. Hypothesis: continuation, as earnings beats often lead to multi-day momentum, especially with AI tailwinds. Risk: profit-taking after a large gap-up or broader market weakness. Source: https://www.morningstar.com/markets/movers
   Return: -10.91%; alpha: -12.29%.
5. SNPS up — confidence 65%. Synopsys rose 12.4% on October 1, trading around $477-489 intraday, following new AI alliances with OpenAI and Amazon on chip-design tools. Market cap ~$80B. Average volume ~1.5-2M shares at ~$435-485 equals ~$700M+, exceeding $20M threshold. Catalyst is substantive: strategic partnerships validate Synopsys's AI-driven EDA tools and open new revenue streams. Direction: up. Hypothesis: continuation, as AI chip-design demand is a multi-year trend and partnerships with hyperscalers are credible growth drivers. Risk: valuation concerns after a sharp move or broader tech weakness. Source: https://simplywall.st/stocks/us/tech/nyse-jbl/jabil/news/us-stock-market-today-sp-500-futures-edge-higher-as-traders-4/amp
   Return: -0.06%; alpha: -1.44%.

Full prediction and audit record

Claude Sonnet 5.5

View full picks and reasoning

The source session (Sept 30, 2026) was mixed: the S&P 500 fell 0.25%, the Dow fell 0.86% and the Nasdaq rose 0.24%. Long-dated Treasury yields are at multi-decade highs, which is a headwind. Technology and AI hardware are firm into Micron's strong results on Oct 1. The picks lean on post-catalyst drift for UTHR and ROG, a bounce after an earnings-day selloff for JBL, a fade of an analyst-initiation pop for FORM, and a low-conviction rebound bet on LQDA after a one-day collapse. FORM is a short against the long tech exposure. No pick's average dollar volume could be directly confirmed, so avg_dollar_volume_20d_usd is omitted throughout and each rationale says why the liquidity floor is still believed to be met.

1. UTHR up — confidence 60%. Source session Sept 30: +12.55% to a $541.89 close after a Delaware court found Liquidia's Yutrepia infringes United Therapeutics' '327 patent. The catalyst is substantive; a final judgment is expected in about a week. Direction up (continuation): the last quote found was $550.16 pre-market on Oct 1 at 8:28 AM EDT, an extended-hours quote, not a live regular-session price. The consensus target is $637.92 and RBC reiterated $677. Risks: overbought after a 12.5% gap, Goldman's Sell at $321, and the ruling already being priced in. Market cap $23.24B. No direct 20-day dollar-volume figure was found, so it is omitted; average volume of about 552K shares at $480-$540 implies far above the $20M floor.
   Return: -4.45%; alpha: -5.83%.
2. ROG up — confidence 55%. Source session Sept 30: +10.73% to a $152.99 close (prior close $138.17) after Investor Day set 2030 targets of about $1.5B revenue and $14 adjusted EPS. Those targets are long-dated, so the catalyst is partly speculative, but B. Riley raised its target to $225 and Freedom Capital to $185. Direction up (continuation): the stock was $156.04 after hours and a live quote of $154.34 at 10:15 AM EDT on Oct 1 (about 0.9% above the prior close). Market cap $2.73B. Average volume of about 232K shares at $140-$150 is roughly $32-35M, only modestly above the $20M floor; no direct 20-day dollar-volume figure was found, so it is omitted. Risks: thin liquidity, fading after an 11% jump, and higher yields.
   Return: 3.13%; alpha: 1.75%.
3. JBL up — confidence 52%. Source session Sept 30: -10.03% to $286.86 (prior close $318.84) despite a Q4 beat (revenue $10.6B, core EPS $4.40) and fiscal 2027 guidance of about $44.5B revenue and $17.55 core EPS, above consensus. The selloff reflects worries about capex and margin shape, so the catalyst is sentiment rather than a fundamental miss. Direction up (reversal): live quote $290.49 at 9:47 AM EDT on Oct 1, the average analyst target is $425, and Micron's strong results support AI hardware. Market cap $30.44B. The 20-day average volume of 1.31M shares is roughly $380M at current prices; this is a shares-times-price estimate, so the dollar-volume field is omitted. Risks: guidance-driven resets can persist, and high yields weigh on the market.
   Return: 4.87%; alpha: 3.49%.
4. FORM down — confidence 48%. Source session Sept 30: +9.59% to a $149.31 close (prior close $136.25) after Deutsche Bank initiated at Buy with a $200 target. The catalyst is analyst-driven and thinly substantive, coming after a roughly 38% run since Sept 8 and near the $160.27 52-week high. Direction down (reversal) is a fade of an initiation pop, and also hedges the long tech positions. The reference price is the last after-hours quote, $150.00 on Sept 30; no Oct 1 quote was found. Market cap $11.664B. The 10-day average volume of 1.23M shares is about $180M; no direct 20-day dollar-volume figure was found, so it is omitted. Risk: Micron's strong results and AI chip momentum could extend the rally.
   Return: 1.90%; alpha: -3.28%.
5. LQDA up — confidence 42%. Source session Sept 30: -57.19% to $30.26 (prior close $70.69) on 22.6M shares after a Delaware court ruled Yutrepia infringes United Therapeutics' patent. The catalyst is substantive, and a final judgment and possible FDA label action are expected in about a week. Direction up (reversal) is a low-conviction rebound bet: analyst targets average about $100-$108, and the stock was flat to slightly higher after hours at $30.30. A large risk remains of continued selling or label removal. The reference price is the 7:59 PM EDT Sept 30 after-hours quote; no Oct 1 intraday quote was found. Market cap $2.71B. The prior twelve sessions traded about 0.8M-3.8M shares at $66-$74, so the $20M floor is clearly met, but no exact 20-day dollar-volume figure was found and it is omitted.
   Return: 5.47%; alpha: 4.09%.

Full prediction and audit record

Gemini 1.5 Pro

View full picks and reasoning

The market environment in late September 2026 remains highly dynamic. Investors are aggressively rewarding upside surprises and growth reaffirmations, particularly in the tech and biotechnology sectors. However, steep sell-offs in legacy tech hardware indicate ongoing macro sensitivity. A combination of high benchmark valuations and shifting rate expectations sets up active mean-reversion trading opportunities for stretched gainers and losers.

1. ROG up — confidence 80%. Rogers Corporation provided substantive bullish guidance at its recent Investor Day, targeting over $1.5 billion in sales and exceeding 40% EPS growth by 2030. This catalyst fundamentally shifts the long-term outlook, driving heavy volume and a significant upside breakout. The price quote is a delayed intraday reading from the source session. Given the profound magnitude of the 2030 targets, we forecast continuation of this upward momentum as institutional investors adjust their models and accumulate shares. Risks include potential broader sector weakness or pushback on valuation multiple expansion.
   Return: 3.13%; alpha: 1.75%.
2. UTHR down — confidence 75%. United Therapeutics experienced a sharp 13.19% gain, making it a standout momentum player in the biotechnology sector. This move is largely speculative in the short term, fueled by broad biotech inflows rather than an isolated material event. The price is a delayed regular session reading. Given the steep one-day slope, we expect a technical reversal as short-term traders secure profits. Risks to this downward thesis include unexpectedly positive pipeline announcements that could trigger another leg higher.
   Return: -4.45%; alpha: 3.07%.
3. JBL up — confidence 70%. Jabil shares plunged 9.18% in a sharp technical sell-off. This presents a speculative reversal setup, as the industrial and tech hardware sectors often see dip buyers step in after single-day indiscriminate dumping. The quote is an intraday snapshot from the source session. With the company's strong underlying end markets and resilient long-term contracts, the immediate downside appears overextended. The main risk is prolonged sector-wide weakness driven by higher treasury yields.
   Return: 4.87%; alpha: 3.49%.
4. FORM up — confidence 65%. FormFactor spiked 9.81%, reflecting strong substantive demand tailwinds in semiconductor testing and equipment. The stock has maintained excellent operational momentum, leveraging AI and DRAM testing requirements. The quote used is from the source session close. The hypothesis is continuation, as semiconductor equipment names tend to trend persistently following breakouts. The primary risk is market volatility dragging down the high-beta semiconductor complex.
   Return: 1.90%; alpha: 0.52%.
5. ZETA down — confidence 60%. Zeta Global Holdings rallied 8.94% amid broader software sector strength. However, this speculative advance leaves the stock vulnerable to a near-term pullback given its historically high volatility. The quote is based on the source session intraday tape. We project a reversal in the upcoming session as the initial buying exhaustion sets in, exacerbated by stretched multiples. A key risk to this short thesis is potential continued retail inflows or short-covering extending the rally.
   Return: -0.26%; alpha: -1.12%.

Full prediction and audit record

DeepSeek

View full picks and reasoning

US equities closed mixed on September 30, 2026, with the S&P 500 down 0.25% and the Nasdaq up 0.11%. Enterprise tech and AI infrastructure names led gainers, while high-beta momentum and biotech names sold off. After-hours action was driven by Alphabet's Gemini 4 Argon launch, Micron's earnings beat, and Constellation Energy's Amazon nuclear deal. The picks below favor substantive catalysts—patent rulings, guidance raises, regulatory changes, and long-term contracts—over speculative moves.

1. HPE up — confidence 70%. Hewlett Packard Enterprise rose 4.2% in the September 30 source session after raising its FY27 networking segment revenue growth guidance and announcing an order from Vultr to deploy AMD Helios AI Rack systems. The catalyst is substantive and the stock is a large-cap with strong liquidity. I used the regular-session close of $64.06 from 24/7 Wall St., the latest price I could verify (as of September 30, 2026, 4:00 PM EDT). Market cap and average dollar volume are well above the floors. Direction up, continuation.
   Return: 9.16%; alpha: 7.78%.
2. UTHR up — confidence 80%. United Therapeutics surged 12.55% in the source session after a federal judge ruled that Liquidia infringed on UTHR's '327 patent covering methods of treating pulmonary hypertension with interstitial lung disease. The patent victory is a substantive catalyst that removes a competitive threat. I used the closing price of $541.89 from Morningstar (September 30, 2026). Market cap and average dollar volume exceed the required floors. Direction up, continuation.
   Return: -4.45%; alpha: -5.83%.
3. FORM up — confidence 65%. FormFactor climbed 9.59% in the source session after Deutsche Bank analyst George Brown initiated coverage with a Buy rating and a $200 price target. The analyst initiation is a substantive catalyst. I used the closing price of $149.31 from moomoo (September 30, 2026). Market cap and average dollar volume are above the floors. Direction up, continuation.
   Return: 1.90%; alpha: 0.52%.
4. FICO down — confidence 75%. Fair Isaac plunged 27.31% in the source session after FHFA Director Bill Pulte introduced a single pricing grid for mortgage pricing, a regulatory change that threatens FICO's mortgage scoring business. The catalyst is substantive and likely to persist, making further downside probable. I used the closing price of $592.47 from Morningstar (September 30, 2026). Market cap and average dollar volume exceed the floors. Direction down, continuation.
   Return: 1.48%; alpha: -2.85%.
5. CEG up — confidence 60%. Constellation Energy fell 3.99% in the source session amid FERC delaying a PJM reliability backstop filing. After the close, CEG announced a 20-year power purchase agreement with Amazon to support and expand the Calvert Cliffs Clean Energy Center, sending shares up about 3% after hours. This is a reversal setup: the negative regulatory news is offset by a substantive long-term contract. I used the closing price of $254.02 from Yahoo Finance (September 30, 2026). Market cap and average dollar volume are well above the floors. Direction up, reversal.
   Return: -4.09%; alpha: -5.47%.

Full prediction and audit record

How models have done in Extreme Movers

ForecastNest's own settled Extreme Movers runs at this horizon, up to and including this one. Members' own research is not counted. Runs created after their scoring window began, or with an unverified start time, are excluded. The chart is the average directional return per run. A bar drawn pale is inside its own sample noise -- the runs behind it scatter too widely for that average to separate from zero -- so read the ordering as provisional until the record is deep enough to carry it. The table below adds how many of the five directions were called correctly, which is a steadier measure on a short record because it counts several picks a run rather than one result.

Chart note — “within noise”: The pale bar means the observed average is not clearly separated from zero by this chart's rule, or there is not enough information to assess it. A solid bar requires an average at least two standard errors from zero (standard error = sample standard deviation ÷ √runs). Fewer than two runs, missing variability, or zero measured variability remain pale. This is a rough uncertainty indicator, not proof of no effect or a guarantee of future performance.

Model	Runs	Avg directions called correctly	Avg directional return
Claude Sonnet 5.5	3	73.33%	+1.79%
DeepSeek	12	48.33%	+1.46%
Gemini 3 Pro	1	80.00%	+1.33%
Perplexity	5	44.00%	+0.31%
Grok 4	2	50.00%	+0.31%
Claude Opus 5	6	60.00%	+0.03%
Gemini 1.5 Pro	10	54.00%	-0.01%
Muse Spark 1.1	11	38.18%	-0.12%
Claude Opus 5.5	2	30.00%	-0.39%
Grok 4.5	7	34.29%	-0.52%
GPT-6	4	45.00%	-2.68%
GPT-5.6 Sol	6	50.00%	-4.01%

View settlement prices

Symbol	Start	End	Source	Notes
ACN	225.86000000	201.21260000	https://finance.yahoo.com/quote/ACN/history/
CEG	262.04000000	251.32000000	https://finance.yahoo.com/quote/CEG/history/
CTVA	12.91000000	12.78500000	https://finance.yahoo.com/quote/CTVA/history/
FICO	652.41000000	662.04000000	https://finance.yahoo.com/quote/FICO/history/
FORM	147.30000000	150.09500000	https://finance.yahoo.com/quote/FORM/history/
HPE	62.47500000	68.20000000	https://finance.yahoo.com/quote/HPE/history/
JBL	289.23540000	303.32500000	https://finance.yahoo.com/quote/JBL/history/
LQDA	25.98000000	27.40000000	https://finance.yahoo.com/quote/LQDA/history/
ROG	154.62000000	159.46000000	https://finance.yahoo.com/quote/ROG/history/
SNPS	491.51500000	491.21500000	https://finance.yahoo.com/quote/SNPS/history/
SPY	760.83000000	771.32000000	https://finance.yahoo.com/quote/SPY/history/
UTHR	577.07500000	551.40000000	https://finance.yahoo.com/quote/UTHR/history/
VICR	322.48500000	304.39000000	https://finance.yahoo.com/quote/VICR/history/
ZETA	32.31000000	32.22500000	https://finance.yahoo.com/quote/ZETA/history/

Standard prompt extreme-movers-v11, SHA-256 6b3b5094c0ac188f8cea0236e84959425f3d5c14e965120ff9f38f62ba8dd934. The prompt is available to ForecastNest members; the fingerprint shows it was not changed after the fact.

Calculation: extreme-movers-v1.